Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.02 +1.0%	$1.86	$1.60 ▼ $2.66	$778.52M	1.06	1.30 million shs	3.07 million shs
LENZ LENZ Therapeutics	$28.71 -2.3%	$25.61	$14.42 ▼ $38.93	$808.07M	0.41	184,156 shs	214,492 shs
NUVB Nuvation Bio	$2.19 -2.2%	$2.03	$1.54 ▼ $3.97	$745.18M	1.42	2.32 million shs	8.00 million shs
TNGX Tango Therapeutics	$1.94 -5.4%	$1.47	$1.03 ▼ $12.02	$210.28M	1.02	1.27 million shs	1.71 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	+1.00%	-2.42%	+10.38%	+1.00%	-24.63%
LENZ LENZ Therapeutics	-2.35%	+1.95%	+5.28%	+34.85%	+86.55%
NUVB Nuvation Bio	-2.23%	+7.62%	+1.39%	+11.45%	-26.01%
TNGX Tango Therapeutics	-5.37%	+2.65%	+30.20%	-11.01%	-71.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	1.6281 of 5 stars	0.0	5.0	3.4	0.0	1.3
LENZ LENZ Therapeutics	1.962 of 5 stars	3.6	0.0	3.6	2.5	0.0
NUVB Nuvation Bio	3.5174 of 5 stars	4.6	0.0	2.7	5.0	0.6
TNGX Tango Therapeutics	2.1144 of 5 stars	3.5	1.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
LENZ LENZ Therapeutics	3.17	Buy	$46.60	62.31% Upside
NUVB Nuvation Bio	3.17	Buy	$7.83	257.69% Upside
TNGX Tango Therapeutics	3.00	Buy	$12.20	528.87% Upside

Current Analyst Ratings Breakdown

Latest TNGX, LENZ, NUVB, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00
5/8/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/23/2025	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$6.00
4/23/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$6.00
4/16/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/14/2025	LENZ LENZ Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$38.00 ➝ $51.00
4/14/2025	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
3/27/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/20/2025	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$44.00 ➝ $47.00
3/18/2025	LENZ LENZ Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$124.59M	6.25	N/A	N/A	$2.87 per share	0.70
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$22.06 per share	N/A
NUVB Nuvation Bio	$10.96M	68.01	N/A	N/A	$2.76 per share	0.79
TNGX Tango Therapeutics	$40.99M	5.13	N/A	N/A	$2.48 per share	0.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	-$73.96M	$0.13	N/A	67.33	1.74	-42.65%	-2.56%	-2.47%	8/14/2025 (Estimated)
LENZ LENZ Therapeutics	-$124.65M	-$1.77	N/A	N/A	N/A	N/A	-58.48%	-55.50%	8/13/2025 (Estimated)
NUVB Nuvation Bio	-$75.80M	-$2.35	N/A	N/A	N/A	N/A	-21.89%	-17.86%	8/4/2025 (Estimated)
TNGX Tango Therapeutics	-$101.74M	-$1.22	N/A	N/A	N/A	-284.42%	-49.64%	-32.00%	8/6/2025 (Estimated)

Latest TNGX, LENZ, NUVB, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million
3/19/2025	Q4 2024	LENZ LENZ Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	24.24	23.05
LENZ LENZ Therapeutics	N/A	28.63	28.63
NUVB Nuvation Bio	N/A	9.57	9.57
TNGX Tango Therapeutics	N/A	8.00	8.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
LENZ LENZ Therapeutics	54.32%
NUVB Nuvation Bio	61.67%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	7.30%
LENZ LENZ Therapeutics	38.40%
NUVB Nuvation Bio	29.93%
TNGX Tango Therapeutics	6.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.41 million	356.14 million	Optionable
LENZ LENZ Therapeutics	110	28.15 million	16.94 million	N/A
NUVB Nuvation Bio	60	340.26 million	319.50 million	Optionable
TNGX Tango Therapeutics	90	108.39 million	100.65 million	Optionable

TNGX, LENZ, NUVB, and CRON Headlines

Recent News About These Companies

Woodline Partners LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 28 at 4:30 AM | marketbeat.com

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 27 at 10:32 PM | finance.yahoo.com

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 27 at 7:00 AM | globenewswire.com

Tango Therapeutics starts trial for brain cancer drug

May 23, 2025 | uk.investing.com

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

May 21, 2025 | globenewswire.com

517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.

May 19, 2025 | marketbeat.com

Q2 EPS Estimate for Tango Therapeutics Increased by Analyst

May 17, 2025 | marketbeat.com

Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 17, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price

May 16, 2025 | finance.yahoo.com

Orbimed Advisors LLC Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 15, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPS

May 14, 2025 | marketbeat.com

Tango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline Developments

May 14, 2025 | nasdaq.com

Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 13, 2025 | finanznachrichten.de

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 13, 2025 | finance.yahoo.com

Tango Therapeutics Extends Cash Runway Amid Clinical Progress

May 13, 2025 | tipranks.com

Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates

May 12, 2025 | zacks.com

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 12, 2025 | globenewswire.com

4,000,000 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Farallon Capital Management LLC

May 11, 2025 | marketbeat.com

Balyasny Asset Management L.P. Has $10.13 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 11, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by Analysts

May 11, 2025 | marketbeat.com

Tango Therapeutics (TNGX) to Release Quarterly Earnings on Monday

May 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX, LENZ, NUVB, and CRON Company Descriptions

Cronos Group NASDAQ:CRON

$2.02 +0.02 (+1.00%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$2.03 +0.01 (+0.50%)

As of 08:00 AM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

LENZ Therapeutics NASDAQ:LENZ

$28.71 -0.69 (-2.35%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$28.66 -0.05 (-0.17%)

As of 05/28/2025 04:24 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Nuvation Bio NYSE:NUVB

$2.19 -0.05 (-2.23%)

Closing price 05/28/2025 03:59 PM Eastern

Extended Trading

$2.23 +0.04 (+1.83%)

As of 08:01 AM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Tango Therapeutics NASDAQ:TNGX

$1.94 -0.11 (-5.37%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.99 +0.05 (+2.58%)

As of 08:05 AM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time